



CORRIGENDUM

## Joint statement for the diagnosis, management, and prevention of chronic obstructive pulmonary disease for Gulf Cooperation Council countries and Middle East-North Africa region, 2017 [Corrigendum]

Mahboub BH, Vats MG, Al Zaabi A, Iqbal MN, Safwat T, Al-Hurish F, Miravittles M, Singh D, Asad K, Zeineldine S, Al-Hajjaj MS. *Int J Chron Obstruct Pulmon Dis*. 2017;12: 2869–2890.

Page 2885, Disclosure, the text “The authors report no conflicts of interest in this work” should read “BHM has a pending patent for Samsun sublingual immunotherapy with the US Patent and Trademark Office. MM has received speaker fees from Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, CSL Behring, Grifols and Novartis; consultancy fees from Boehringer Ingelheim, Chiesi,

GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratories Esteve, Mereo BioPharm, Verona Pharma, pH Pharma, Novartis and Grifols; and research grants from GlaxoSmithKline and Grifols. DS has received speaking/ consultancy fees from Apellis, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Genentech, Glenmark, Merck, Mundipharma, Novartis, Peptinnovate, Pfizer, Pulmatrix, Skyepharma, Therevance and Verona; and research grants from AstraZeneca, Boehringer Ingelheim, Chiesi, Glenmark, Merck, Mundipharma, Novartis, Pfizer, Pulmatrix, Teva, Therevance and Verona. The authors report no other conflicts of interest in this work”.

International Journal of COPD

Dovepress

### Publish your work in this journal

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols.

This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal>

submit your manuscript | [www.dovepress.com](http://www.dovepress.com)



<http://dx.doi.org/10.2147/COPD.S194431>

International Journal of COPD 2019:14 115



© 2019 Mahboub et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <https://www.dovepress.com/terms.php> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<http://creativecommons.org/licenses/by-nc/3.0/>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<https://www.dovepress.com/terms.php>).

115